uniQure (NASDAQ:QURE) Sees Large Volume Increase – Here’s What Happened

uniQure (NASDAQ:QURE) shares saw unusually-high trading volume on Wednesday . Approximately 681,525 shares traded hands during mid-day trading, a decline of 27% from the previous session’s volume of 930,653 shares.The stock last traded at $16.08 and had previously closed at $17.64.

Analyst Upgrades and Downgrades

QURE has been the topic of several research reports. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday, December 11th. The Goldman Sachs Group increased their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Mizuho increased their price target on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. Finally, Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $33.88.

uniQure Stock Down 13.0 %

The firm has a 50 day moving average price of $11.23 and a 200-day moving average price of $7.96. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $675.09 million, a PE ratio of -2.79 and a beta of 0.41.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Research analysts forecast that uniQure will post -3.82 EPS for the current fiscal year.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.74% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. RTW Investments LP acquired a new position in uniQure during the third quarter worth $49,000. China Universal Asset Management Co. Ltd. boosted its position in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares in the last quarter. Atria Investments Inc purchased a new stake in uniQure during the third quarter worth $53,000. Quarry LP purchased a new stake in uniQure during the third quarter worth $58,000. Finally, Vanguard Personalized Indexing Management LLC boosted its position in uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.